Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Immune checkpoint inhibitors (ICIs) improve the outcomes of several types of cancer. However, they are also associated with various immune-related adverse events including myocarditis. ICI-induced myocarditis is a rare, potentially life-threatening adverse event. We herein report two cases of corticosteroid-refractory ICI-induced myocarditis. In both cases, additional immunosuppressive therapies, such as intravenous immunoglobulin and tacrolimus, successfully resolved myocarditis. Given the corticosteroid-refractory nature of these cases, we suggest that prompt addition of other immunosuppressive drugs to corticosteroid therapy should be considered in the treatment of ICI-induced myocarditis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097839 | PMC |
| http://dx.doi.org/10.2169/internalmedicine.4162-24 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study.
Eur Heart J
August 2025
Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe PEPITES, 47 Boulevard de l'Hopital, Paris 75013, France.
Background And Aims: Immune checkpoint inhibitor (ICI)-induced (cardio)-myotoxicities, including myocarditis and myositis, are uncommon but frequently severe adverse drug reactions seen in cancer patients. Real-life ICI myotoxicity incidence estimates span from limited-size cohorts, with risk factors and prognosticators poorly established, as well as their impact on survival.
Methods: This retrospective French National Health Data System cohort study included all adult patients starting ICI between 1 January 2012 and 30 September 2022.
Immune Checkpoint Inhibitor-Induced Myositis Myocarditis and Myasthenia Gravis (MMM) Overlap Syndrome in a Rural District General Hospital: An Institutional Case Series Involving Four Patients.
Cureus
August 2025
Acute Oncology, Hywel Dda University Health Board, Haverfordwest, GBR.
Immune checkpoint inhibitors (ICIs) are commonly used for the treatment of some advanced cancers. Although effective, they can cause side effects. This case series describes four patients treated for ICI-induced myositis, myocarditis and myasthenia gravis (MMM) overlap syndrome at a rural general hospital in the United Kingdom between 2023 and 2025.
View Article and Find Full Text PDFRisk factors and diagnostic biomarkers for asymptomatic immune checkpoint inhibitor-related myocarditis in patients with esophageal cancer after immunotherapy.
World J Gastroenterol
July 2025
Department of Radiotherapy, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.
Background: Esophageal cancer is a serious global health concern with poor prognosis in advanced stages. Immune checkpoint inhibitors (ICIs) have shown promise in enhancing survival, but they are associated with immune-related adverse events, including potentially life-threatening myocarditis. Moreover, ICI-induced myocarditis can be asymptomatic, necessitating early diagnosis.
View Article and Find Full Text PDFImmune checkpoint inhibitors and cardiovascular toxicity: immunology, pathophysiology, diagnosis, and management.
J Thromb Thrombolysis
July 2025
Cardiovascular-Oncology Program, University of Cincinnati Cancer Center, Cincinnati, OH, 45267, USA.
Immune checkpoint inhibitors (ICIs) are pivotal in cancer therapy, particularly but not solely for metastatic and advanced lung cancer. These monoclonal antibodies, targeting programmed cell death (PD)-1, ligand PD-L1, and cytotoxic T-lymphocyte antigen (CTLA)-4, enhance immune responses against tumors but can also trigger immune-related adverse events, including cardiotoxicity and vascular toxicity. Cardiotoxic effects, such as myocarditis, pericarditis, atrial arrhythmias, thrombosis, and vasculitis are significant concerns, particularly myocarditis that can be fatal.
View Article and Find Full Text PDFCase Report: Immune checkpoint inhibitor-induced myositis without elevated creatine kinase.
Front Immunol
July 2025
Department of Dermatology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced cancers like malignant melanoma. However, they can lead to a range of immune-related adverse events (irAEs), impacting various organ systems. Among these, myositis is a rare but serious irAE, typically characterized by myalgia, muscle weakness, and elevated creatine kinase (CK) levels.
View Article and Find Full Text PDF